Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + celecoxib + XELOX versus XELOX perioperative therapy for resectable locally advanced gastric adenocarcinoma
ChiCTR2300076761Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cadonilimab, celecoxib, capecitabine and oxaliplatin in gastric adenocarcinoma (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Pathologic complete response rate. Started Aug 2023; status: recruiting.
02
Drugs
cadonilimabcelecoxibcapecitabineoxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300076761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076761.